Keros Therapeutics Inc · Q4 2022 earnings

Briefing

Reported financial results for the fourth quarter and full year ended December 31, 2022.

Keros Therapeutics reported a net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022. The increase in net loss for the fourth quarter and the increase in net loss for the year was largely due to increased research and development efforts, including the progression of the Company's two Phase 2 clinical trials in KER-050, one in patients with MDS and one in patients with myelofibrosis, plus an upfront payment from the Company's license agreement with Hansoh in the fourth quarter of 2021. The Company expects that its cash and cash equivalents as of December 31, 2022, together with the net proceeds from the ATM through February 28, 2023, will enable the Company to fund its operating expenses and capital expenditure requirements into the third quarter of 2025.

• Keros reported a net loss of $29.7 million for the fourth quarter of 2022.
• Research and development expenses were $24.9 million for the fourth quarter of 2022.
• General and administrative expenses were $7.1 million for the fourth quarter of 2022.
• Cash and cash equivalents as of December 31, 2022 was $279.0 million.

Headline financials

Revenue & EPS history